Clinical trials: Macular Degeneration
Neovascular Age-related Macular Degeneration, Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT06176963
- Testing
- SB11 PFS
- Where
- 3 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-related Macular Degeneration
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF)…
- Trial name
- NCT03869684
- Testing
- MT-0814
- Where
- 13 sites in United States
- Volunteers
- 13 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Geographic Atrophy
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in…
- Trial name
- NCT02288559
- Testing
- Lampalizumab
- Where
- 36 sites in United States
- Volunteers
- 96 people
- Sponsor
- Genentech, Inc.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Stargardt's Macular Dystrophy
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
- Trial name
- NCT03364153
- Testing
- avacincaptad pegol
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 121 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Exudative Age-related Macular Degeneration
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
- Trial name
- RAMEN (NCT04640272)
- Testing
- RBM-007
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ribomic USA Inc
Neovascular Age-Related Macular Degeneration
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
- Trial name
- NCT01926977
- Testing
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Neovascular Age-related Macular Degeneration
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
- Trial name
- COAST (NCT04757636)
- Testing
- 2.0 mg OPT-302, 2.0 aflibercept
- Where
- 209 sites in United States, Argentina and 28 more
- Volunteers
- 998 people
- Sponsor
- Opthea Limited
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion.
- Trial name
- MIVI-5 (NCT00913744)
- Testing
- Ocriplasmin
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- ThromboGenics
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Age Related Macular Degeneration
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.
- Trial name
- NCT00446654
- Testing
- CGC-11047
- Where
- 8 sites in United States, Mexico and 1 more
- Volunteers
- 43 people
- Sponsor
- Progen Pharmaceuticals
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Study EvAluating Genotypes While Using Lucentis 2
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
- Trial name
- SEAGUL2 (NCT01464723)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Diego
Uveitis
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
The objective of this study is to investigate the safety and efficacy of microplasmin as a treatment for uveitic macular edema.
- Trial name
- MIME (NCT01194674)
- Testing
- Microplasmin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.